Preeti Dubey, Yingye Fang, K Lionel Tukei, Shobhan Kuila, Xinming Liu, Annika Sahota, Antonina I Frolova, Erin L Reinl, Manasi Malik, Sarah K England, Princess I Imoukhuede
Approximately half of U.S. women giving birth annually receive Pitocin, the synthetic form of oxytocin (OXT), yet its effective dose can vary significantly. This variability presents safety concerns due to unpredictable responses, which may lead to adverse outcomes for both mother and baby. To address the need for improved dosing, we developed a data-driven mathematical model to predict OXT receptor (OXTR) binding. Our study focuses on five prevalent OXTR variants (V45L, P108A, L206V, V281M, and E339K) and their impact on OXT-OXTR binding dynamics in two distinct cell types: human embryonic kidney cells (HEK293T), commonly used in experimental systems, and human myometrial smooth muscle cells, containing endogenous OXTR...
March 16, 2024: bioRxiv